You are here:

caspofungin acetate (Caspofungin)

Advice

following a a full submission:

caspofungin acetate (Caspofungin) is not recommended for use within NHS Scotland.

Efficacy and safety data provided to support the possible benefits of caspofungin in the treatment of invasive aspergillosis were extremely limited, and in the form of one small, open-label, uncontrolled study. This evidence is not considered sufficiently robust to justify a recommendation for use at present.

The applicant company has since confirmed that the results of a randomised clinical trial have been published in December 2002. The SMC will provide a further recommendation on this product once an additional submission has been made and assessed.

Drug Details

Drug Name: caspofungin acetate (Caspofungin)
SMC Drug ID: 30/03
Manufacturer: MSD
Indication: for the treatment of invasive aspergillosis.
BNF Category:
Sub Category: 5.2 Antifungal Drugs
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 7 March 2003

Back